— Know what they know.
Not Investment Advice
Also trades as: VBIO (OTC) · $vol 0M

MLCT OTC

Malachite Innovations, Inc.
1W: +16.9% 1M: +111.0% 3M: +137.5% 1Y: +111.1% 3Y: +280.0% 5Y: -41.5%
$0.20
Last traded 2024-01-12 — delisted
OTC · Healthcare · Biotechnology · $17.5M mcap · 65M float · 0.019% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$17.5M
52W Range0.1-0.43
Volume18,285
Avg Volume12,251
Beta2.11
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOMichael R. Cavanaugh CPA,
Employees74
SectorHealthcare
IndustryBiotechnology
IPO Date2012-03-27
200 Park Avenue
Cleveland, OH 44122
US
216 304 6556
About Malachite Innovations, Inc.

Malachite Innovations, Inc., established in Cleveland, Ohio, in 2007, pursues a dual business strategy. Operating through its subsidiaries, the company delivers health and wellness products across the United States, featuring a comprehensive collection of nearly 100 innovative cannabosides, including glycosylated tetrahydrocannabinol, cannabidiol, cannabidivarin, and cannabinol. The firm is also advancing the development of THC-glycoside (VBX-100), an oral prodrug intended for treating gastrointestinal conditions such as inflammatory bowel disease and irritable bowel syndrome. Additionally, Malachite Innovations dedicates efforts to identifying, funding, and revitalizing environmental ventures, prioritizing advanced technology and sustainable practices. The company adopted its current name in October 2021, having previously operated as Vitality Biopharma, Inc.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
FEIGHAN EDWARD F A-Award 250,000 $0.21 2023-12-21
Cavanaugh Michael R. A-Award 1,000,000 $0.21 2023-12-21
Celeste Richard F A-Award 250,000 $0.21 2023-12-21
Cavanaugh Michael R. P-Purchase 1,000,000 $0.15 2023-12-21
FEIGHAN EDWARD F P-Purchase 666,667 $0.15 2023-12-21

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms